SpectraCure AB (publ) OMXSTO:SPEC:
Q1 2026 OTHER OPERATING INCOME AMOUNTED TO 310 TSEK
Q1 2026 NET RESULT AFTER TAX WAS -6139 TSEK
Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
Earlier from SpectraCure
- SPEC: Promising clinical progress, but widened losses and liquidity risks raise going concern doubts
- Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
- Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
- Spectracure Q3 Net Loss SEK 35 Mln
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
Later from SpectraCure
All SpectraCure news releasesFollow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure